These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8625532)

  • 1. Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy.
    Wadhwa M; Bird C; Fagerberg J; Gaines-Das R; Ragnhammar P; Mellstedt H; Thorpe R
    Clin Exp Immunol; 1996 May; 104(2):351-8. PubMed ID: 8625532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF.
    Wadhwa M; Skog AL; Bird C; Ragnhammar P; Lilljefors M; Gaines-Das R; Mellstedt H; Thorpe R
    Clin Cancer Res; 1999 Jun; 5(6):1353-61. PubMed ID: 10389919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy.
    Ragnhammar P; Wadhwa M
    Med Oncol; 1996 Sep; 13(3):161-6. PubMed ID: 9106175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients.
    Ragnhammar P; Friesen HJ; Frödin JE; Lefvert AK; Hassan M; Osterborg A; Mellstedt H
    Blood; 1994 Dec; 84(12):4078-87. PubMed ID: 7994026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and IL-2.
    Hjelm Skog AL; Wadhwa M; Hassan M; Gharizadeh B; Bird C; Ragnhammar P; Thorpe R; Mellstedt H
    Clin Cancer Res; 2001 May; 7(5):1163-70. PubMed ID: 11350880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF).
    Rini B; Wadhwa M; Bird C; Small E; Gaines-Das R; Thorpe R
    Cytokine; 2005 Jan; 29(2):56-66. PubMed ID: 15598439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated With GM-CSF (Sargramostim) as Adjuvant Therapy of Melanoma.
    Spitler LE; Cao H; Piironen T; Whiteside TL; Weber RW; Cruickshank S
    Am J Clin Oncol; 2017 Apr; 40(2):207-213. PubMed ID: 25286079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation.
    Ullenhag G; Bird C; Ragnhammar P; Frödin JE; Strigård K; OIsterborg A; Thorpe R; Mellstedt H; Wadhwa M
    Clin Immunol; 2001 Apr; 99(1):65-74. PubMed ID: 11286542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.
    Liljefors M; Nilsson B; Mellstedt H; Frödin JE
    Cancer Immunol Immunother; 2008 Mar; 57(3):379-88. PubMed ID: 17676322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.
    Hjelm Skog A; Ragnhammar P; Fagerberg J; Frödin J; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H
    Cancer Immunol Immunother; 1999 Nov; 48(8):463-70. PubMed ID: 10550551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease.
    Meager A; Wadhwa M; Bird C; Dilger P; Thorpe R; Newsom-Davis J; Willcox N
    Immunology; 1999 Jul; 97(3):526-32. PubMed ID: 10447777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
    Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin JE
    Int J Oncol; 2005 Jun; 26(6):1581-9. PubMed ID: 15870873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of functionally distinct domains of human granulocyte-macrophage colony-stimulating factor using monoclonal antibodies.
    Kanakura Y; Cannistra SA; Brown CB; Nakamura M; Seelig GF; Prosise WW; Hawkins JC; Kaushansky K; Griffin JD
    Blood; 1991 Mar; 77(5):1033-43. PubMed ID: 1704802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1A in combination with GM-CSF in the treatment of colorectal carcinoma (CRC).
    Ragnhammar P; Magnusson I; Masucci G; Mellstedt H
    Med Oncol Tumor Pharmacother; 1993; 10(1-2):61-70. PubMed ID: 8258997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor.
    Shetye J; Ragnhammar P; Liljefors M; Christensson B; Frödin JE; Biberfeld P; Mellstedt H
    Clin Cancer Res; 1998 Aug; 4(8):1921-9. PubMed ID: 9717820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced.
    Ragnhammar P; Fagerberg J; Frödin JE; Hjelm AL; Lindemalm C; Magnusson I; Masucci G; Mellstedt H
    Int J Cancer; 1993 Mar; 53(5):751-8. PubMed ID: 8449598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies that recognize human granulocyte-macrophage colony-stimulating factor and neutralize its bioactivity in vitro.
    Dempsey PJ; Layton JE; Duhrsen U; Nicola NA; Cebon J; Burgess AW; Morstyn G
    Hybridoma; 1990 Dec; 9(6):545-58. PubMed ID: 1706312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF.
    Krinner EM; Raum T; Petsch S; Bruckmaier S; Schuster I; Petersen L; Cierpka R; Abebe D; Mølhøj M; Wolf A; Sørensen P; Locher M; Baeuerle PA; Hepp J
    Mol Immunol; 2007 Feb; 44(5):916-25. PubMed ID: 16697465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations.
    Wadhwa M; Meager A; Dilger P; Bird C; Dolman C; Das RG; Thorpe R
    Immunology; 2000 Jan; 99(1):113-23. PubMed ID: 10651949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.
    Hernandez-Ilizaliturri FJ; Jupudy V; Reising S; Repasky EA; Czuczman MS
    Leuk Lymphoma; 2005 Dec; 46(12):1775-84. PubMed ID: 16263581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.